Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Ligand Pharm (NQ: LGND ) 98.96 UNCHANGED Streaming Delayed Price Updated: 4:00 PM EDT, Jul 18, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Ligand Pharm < Previous 1 2 3 4 5 6 Next > Ligand Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) February 01, 2024 From Ligand Pharmaceuticals Incorporated Via Business Wire U.S. Food and Drug Administration Approves ZELSUVMI™ as a First-in-Class Medication for the Treatment of Molluscum Contagiosum January 05, 2024 From Ligand Pharmaceuticals Incorporated Via Business Wire Ligand Holds Investor and Analyst Day; Provides Update on Portfolio Progress and Recent Transactions; Introduces 2024 Guidance December 12, 2023 From Ligand Pharmaceuticals Incorporated Via Business Wire Where Ligand Pharmaceuticals Stands With Analysts September 19, 2023 Via Benzinga Analyst Expectations for Ligand Pharmaceuticals's Future August 23, 2023 Via Benzinga Recap: Ligand Pharmaceuticals Q1 Earnings May 04, 2023 Via Benzinga Ligand to Host Investor and Analyst Day on December 12, 2023 in New York City December 06, 2023 From Ligand Pharmaceuticals Incorporated Via Business Wire Palvella Therapeutics and Ligand Pharmaceuticals Expand Strategic Partnership to Accelerate Phase 3 Development of QTORIN™ rapamycin for Microcystic Lymphatic Malformations and Additional High Unmet Need Clinical Indications December 01, 2023 From Palvella Therapeutics Via GlobeNewswire Merck Highlights Data On New Vaccine, Compares 'Tolerability And Safety' To Pfizer's November 28, 2023 Merck & Co Inc (NYSE: MRK) released results from the STRIDE-3 Phase 3 trial evaluating V116, the company's investigational 21-valent Via Benzinga Ligand Reports Third Quarter 2023 Financial Results November 08, 2023 From Ligand Pharmaceuticals Incorporated Via Business Wire Ligand Acquires Royalty on Sanofi’s TZIELD® for $20 Million November 01, 2023 From Ligand Pharmaceuticals Incorporated Via Business Wire Ligand To Report Third Quarter 2023 Financial Results On November 8 October 25, 2023 From Ligand Pharmaceuticals Incorporated Via Business Wire Ovid Therapeutics and Ligand Pharmaceuticals Enter into a $30 Million Agreement for a 13% Interest in Soticlestat Royalties and Milestones Extending Ovid’s Cash Runway into 2026 October 18, 2023 From Ovid Therapeutics Inc. Via GlobeNewswire Ligand Acquires Assets of Novan, Inc. for $12.2 Million September 27, 2023 From Ligand Pharmaceuticals Incorporated Via Business Wire Ligand Appoints Martine Zimmermann to its Board of Directors September 26, 2023 From Ligand Pharmaceuticals Incorporated Via Business Wire Ligand’s Partner Jazz Pharmaceuticals Receives European Commission Approval for Enrylaze® (a recombinant Erwinia asparaginase or crisantaspase) for the Treatment of Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma September 22, 2023 From Ligand Pharmaceuticals Incorporated Via Business Wire Ligand’s Partner Travere Therapeutics Announces Confirmatory Data from the Phase 3 PROTECT Study of FILSPARI® Demonstrating Long-Term Kidney Function Preservation in IgA Nephropathy; Narrowly Missing eGFR Total Slope Endpoint versus Active Control September 21, 2023 From Ligand Pharmaceuticals Incorporated Via Business Wire Ligand Pharma Updates Annual Guidance As It Spins Out Pelican Subsidiary September 19, 2023 Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) entered into a merger agreement under which its subsidiary, Pelican Technology Holdings Inc, has become a wholly owned subsidiary of Primrose Bio... Via Benzinga Ligand Spins Out and Merges Pelican Subsidiary with Primordial Genetics to Form Primrose Bio September 18, 2023 From Ligand Pharmaceuticals Incorporated Via Business Wire Ligand Pharmaceuticals Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) September 01, 2023 From Ligand Pharmaceuticals Incorporated Via Business Wire Ligand Reports Second Quarter 2023 Financial Results August 08, 2023 From Ligand Pharmaceuticals Incorporated Via Business Wire Ligand’s Collaborator Merck Announces V116, an Investigational, 21-valent Pneumococcal Conjugate Vaccine Specifically Designed for Adults, Met Key Immunogenicity and Safety Endpoints in Two Phase 3 Trials July 27, 2023 From Ligand Pharmaceuticals Incorporated Via Business Wire Ligand To Report Second Quarter 2023 Financial Results On August 8 July 25, 2023 From Ligand Pharmaceuticals Incorporated Via Business Wire Why Are Novan Shares Nosediving Today? July 17, 2023 Novan Inc (NASDAQ: NOVN) shares are trading lower after Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced that it has offered to Via Benzinga Ligand Offers $15 Million to Acquire Assets of Novan, Inc. July 17, 2023 From Ligand Pharmaceuticals Incorporated Via Business Wire Novan Enters into Agreement to Sell Substantially All of its Assets, including Berdazimer Gel, 10.3% (SB206), and Files for Chapter 11 Protection July 17, 2023 From Novan, Inc. Via GlobeNewswire 3 Stocks That Smart Investors Should Be Flocking to Now May 30, 2023 Investors may want to detour away from the obvious trades and consider compelling top stocks for smart investors. Via InvestorPlace Viking Therapeutics Outperforms Expectations: Analyst Increases Price Target Following Successful VK2809 Trial May 16, 2023 Ligand Pharmaceuticals Incorporated's (NASDAQ: LGND) partner Viking Therapeutics Inc (NASDAQ: VKTX) announced positive topline results from its Phase 2b trial of VK2809 in Via Benzinga Ligand’s Partner Viking Therapeutics Announces Positive Top-Line Results from Phase 2b VOYAGE Study of VK2809 in Patients with Biopsy-Confirmed Non-Alcoholic Steatohepatitis (NASH) May 16, 2023 From Ligand Pharmaceuticals Incorporated Via Business Wire Ligand Reports First Quarter 2023 Financial Results May 04, 2023 From Ligand Pharmaceuticals Incorporated Via Business Wire < Previous 1 2 3 4 5 6 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.